Group 1 - The company, Maike Bio (300463.SZ), has recently received a Medical Device Registration Certificate from the National Medical Products Administration [1] - The registered product is a cross-matching blood quality control product [1]

Group 1 - The company, Maike Bio (300463.SZ), has recently received a Medical Device Registration Certificate from the National Medical Products Administration for its product, a cross-matching blood quality control reagent [1]

Core Viewpoint - The company, Maike Biological (300463.SZ), has received a medical device registration certificate from the National Medical Products Administration for its new product, cross-matching blood quality control products, which enhances its product portfolio and market competitiveness [1] Group 1 - The newly registered product is intended for quality control in manual and fully automated blood type analysis systems during cross-matching tests [1] - The introduction of this product is expected to positively impact the company's market expansion and future operations [1] - The registration certificate enriches the company's product offerings, contributing to its overall market competitiveness [1]

Core Viewpoint - The company announced that its cross-matching quality control product has received a medical device registration certificate from the National Medical Products Administration, enhancing its product portfolio and market competitiveness [1] Group 1: Product Development - The new product is designed for use with the company's anti-human globulin (anti-IgG+C3d) testing card and is intended for quality control in manual and fully automated blood type analysis systems [1] - The product is specifically for clinical testing and is not intended for blood source screening [1] Group 2: Market Impact - The registration certificate for the new product is expected to positively influence the company's market expansion and future operations [1] - The actual sales performance of the registered product will depend on future marketing efforts, and the impact on the company's future revenue remains unpredictable [1]